Anti-angiogenic therapy in cancer: Downsides and new pivots for precision medicine

Frontiers in Pharmacology

Volumn 7, Issue JAN, 2017, Pages

  Lupo, Gabriella ^a   Caporarello, Nunzia ^a   Olivieri, Melania ^a   Cristaldi, Martina ^a   Motta, Carla ^a   Bramanti, Vincenzo ^a   Avola, Roberto ^a   Salmeri, Mario ^a   Nicoletti, Ferdinando ^a   Anfuso, Carmelina D ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Anti angiogenic therapy; Hypoxia detection; Microvascular architecture; Pericytes; Tumor angiogenesis; Tumor endothelial cells (TECs); Vascular normalization

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; CLINICAL EFFECTIVENESS; DATA ANALYSIS; DRUG EFFICACY; DRUG RESPONSE; HUMAN; MALIGNANT NEOPLASM; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PREDICTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85012108986     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00519     Document Type: Short Survey

References (102)

1. Adya, R., Tan, B. K., Punn, A., Chen, J., and Randeva, H. S. (2008). Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3 K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc. Res. 78, 356-365. doi: 10.1093/cvr/cvm111
2. Allegra, C. J., Yothers, G., O'Connell, M. J., Sharif, S., Petrelli, N. J., Lopa, S. H., et al. (2013). Bevacizumab in stage II-III colon can-cer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J. Clin. Oncol. 31, 359-364. doi: 10.1200/JCO.2012.44.4711
3. Anfuso, C. D., Motta, C., Giurdanella, G., Arena, V., Alberghina, M., and Lupo, G. (2014). Endothelial PKCa-MAPK/ERK-phospholipase A2 pathway activation as a response of glioma in a triple culture model. A new role for pericytes? Biochimie 99, 77-87. doi: 10.1016/j.biochi.2013.11.013
4. Baumann, R., Depping, R., Delaperriere, M., and Dunst, J. (2016). Targeting hypoxia to overcome radiation resistance in head & neck cancers: real challenge or clinical fairytale? Expert Rev. Anticancer Ther. 16, 751-758. doi: 10.1080/14737140.2016.1192467
5. Bennouna, J., Sastre, J., Arnold, D., Osterlund, P., Greil, R., Van Cutsem, E., et al. (2013). Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14, 29-37. doi: 10.1016/S1470-2045(12)70477-1
6. Bergers, G., and Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8, 592-603. doi: 10.1038/nrc2442
7. Brizel, D. M., Schroeder, T., Scher, R. L., Walenta, S., Clough, R. W., Dewhirst, M. W., et al. (2001). Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 51, 349-353. doi: 10.1016/S0360-3016(01)01630-3
8. Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Sienna, S., Bastholt, L., et al. (2014). Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319-328. doi: 10.1016/S0140-6736(14)60421-9
9. Bruix, J., Takayama, T., Mazzaferro, V., Chau, G. Y., Yang, J., Kudo, M., et al. (2015). Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16, 1344-1354. doi: 10.1016/S1470-2045(15)00198-9
10. Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473-2483. doi: 10.1056/NEJMoa1104390
11. Cainap, C., Qin, S., Huang, W. T., Chung, I. J., Pam, H., Cheng, Y., et al. (2015). Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J. Clin. Oncol. 33, 172-179. doi: 10.1200/JCO.2013.54.3298
12. Chen, H. X., and Cleck, J. N. (2009). Adverse effects of anticancer agents that target the VEGF pathway. Nat. Rev. Clin. Oncol. 6, 465-477. doi: 10.1038/nrclinonc
13. Chung, A. S., Kowanetz, M., Wu, X., Zhuang, G., Ngu, H., Finkle, D., et al. (2012). Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J. Pathol. 227, 404-416. doi: 10.1002/path.4052
14. Chung, A. S., Wu, X., Zhuang, G., Ngu, H., Kasman, I., Zhang, J., et al. (2013). An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 19, 1114-1123. doi: 10.1038/nm.3291
15. Cooke, V. G., Lebleu, V. S., Keskin, D., Khan, Z., O'Connell, J. T., Teng, Y., et al. (2012). Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 21, 66-68. doi: 10.1016/j.ccr.2011.11.024
16. Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., et al. (2009). PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21-34. doi: 10.1016/jccr.2008.12.004
17. de Gramont, A., Van Cutse, E., Schmoll, H. J., Tabernero, J., Clarke, S., Moore, M. J., et al. (2012). Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13, 1225-1233. doi: 10.1016/S1470-2045(12)70509-0
18. Dennie, J., Mandeville, J. B., Boxerman, J. L., Packard, S. D., Rosen, B. R., and Weisskoff, R. M. (1998). NMR imaging of changes in vascular morphology due to tumour angiogenesis. Magn. Reson. Med. 1998, 793-799. doi: 10.1002/mrm.1910400602
19. Earl, H. M., Hiller, L., Dunn, J. A., Blenkinsop, C., Grybowicz, L., Vallier, A. L., et al. (2015). Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Lancet Oncol. 16, 656-666. doi: 10.1016/S1470-2045(15)70137-3
20. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., and Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239. doi: 10.1016/j.ccr.2009.01.021
21. Emblem, K. E., Mouridsen, K., Bjornerud, A., Farrar, C. T., Jennings, D., Borra, R. J. H., et al. (2013). Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat. Med. 19, 1178-1183. doi: 10.1038/nm.3289
22. Erapaneedi, R., Belousov, V. V., Schäfers, M., and Kiefer, F. (2016). A novel family of fluorescent hypoxia sensors reveal strong heterogeneity in tumor hypoxia at the cellular level. EMBO J. 35, 102-113. doi: 10.15252/embj.201592775
23. Fakhrejahani, E., and Toi, M. (2014). Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. Jpn. J. Clin. Oncol. 44, 197-207. doi: 10.1093/jjco/hyt201
24. Folberg, R., and Maniotis, A. J. (2004). Vasculogenic mimicry. APMIS 112, 508-525. doi: 10.1111/j.1600-0463.2004.apm11207-0810.x
25. Fuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., et al. (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383, 31-39. doi: 10.1016/S0140-6736(13)61719-5
26. Furuhashi, M., Sjoblom, T., Abramsson, A., Ellingsen, J., Micke, P., Li, H., et al. (2004). Platelet-derived growth factor production by B16 melanoma cells leads to increased pericyte abundance in tumors and an associated increase in tumor growth rate. Cancer Res. 64, 2725-2733. doi: 10.1158/0008-5472.CAN-03-1489
27. Garon, E. B., Ciuleanu, T. E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., et al. (2014). Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384, 665-673. doi: 10.1016/S0140-6736(14)60845
28. Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., et al. (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699-708. doi: 10.1056/NEJMoa1308573
29. Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., et al. (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiol. Rev. 91, 1071-1121. doi: 10.1152/physrev.00038.2010
30. Greenberg, J. I., Shields, D. J., Barillas, S. G., Acevedo, L. M., Murphy, E., Huang, J., et al. (2008). A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456, 809-813. doi: 10.1038/nature07424
31. Grothey, A., Van Cutsem, E., Sobrero, A., Siena, S., Falcone, A., Ychou, M., et al. (2013). Regorafenib monotheraphy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet 381, 303-312. doi: 10.1016/S0140-6736(12)61900-X
32. Gu, L., Zhu, N., Zhang, H., Durden, D. L., Feng, Y., and Zhou, M. (2009). Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 15, 363-375. doi: 10.1016/j.ccr.2009.03.002
33. Hagglof, C., Hammarsten, P., Josefsson, A., Stattin, P., Paulsson, J., Bergh, A., et al. (2010). Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS ONE 5:e10747. doi: 10.1371/journal.pone.0010747
34. Harada, H., Itasaka, S., Zhu, Y., Zeng, L., Xie, X., Morinibu, A., et al. (2009). Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br. J. Cancer 100, 747-757. doi: 10.1038/sj.bjc.6604939
35. Heist, R. S., Dusa, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., et al. (2015). Improved tumour vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 112, 1547-1552. doi: 10.1073/pnas.1424024112
36. Hendriksen, E. M., Span, P. N., Schuuring, J., Peters, J. P., Sweep, F. C., van der Kogel, A. J., et al. (2009). Angiogenesis, hypoxia and VEGF expression during tumour growth in a human xenograft tumourmodel. Microvasc. Res. 77, 96-103. doi: 10.1016/j.mvr.2008.11.002
37. Hernandez-Agudo, E., Mondejar, T., Soto-Montenegro, M. L., Megias, D., Mouron, S., Sanchez, J., et al. (2016). Monitoring vascular normalization induced by antiangiogenic treatment with 18F-fluoromisonidazole-PET. Mol. Oncol. 10, 704-718. doi: 10.1016/j.molonc.2015.12.011
38. Hida, K., Maishi, N., Torii, C., and Hida, Y. (2016). Tumour angiogenesis-characteristics of tumor endothelial cells. Int. J. Clin. Oncol. 21, 206-212. doi: 10.1007/s10147-016-0957-1
39. Hirschhaeuser, F., Sattler, U. G., and Mueller-Klieser, W. (2011). Lactate: a metabolic key player in cancer. Cancer Res. 71, 6921-6925. doi: 10.1158/0008-5472
40. Huang, Y., Goel, S., Duda, D. G., Fukumura, D., and Jain, R. K. (2013). Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73, 2943-2948. doi: 10.1158/0008-5472
41. Hutson, T. E., Escudier, B., Esteban, E., Bjarnason, G. A., Lim, H. Y., Pittman, K. B., et al. (2014). Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 32, 760-767. doi: 10.1200/JCO.2013.50.3961
42. Jain, R. K. (2013). Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205-2218. doi: 10.1200/JCO.2012.46.3653
43. Jeong, H. S., Jones, D., Liao, S., Wattson, D. A., Cui, C. H., Duda, D. G., et al. (2015). Investigation of the lack of angiogenesis in the formation of lymph node metastases. J. Natl. Cancer Inst. 107:djv155. doi: 10.1093/jnci/djv155
44. Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A., Fack, F., et al. (2011). Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc. Natl. Acad. Sci. U.S.A. 108, 3749-3754. doi: 10.1073/pnas.1014480108
45. Kilarski, W. W., Samolov, B., Petersson, L., Kvanta, A., and Gerwins, P. (2009). Biomechanical regulation of blood vessel growth during tissue vascularization. Nat. Med. 15, 657-664. doi: 10.1038/nm.1985
46. Kim, H. L., Yeo, E. J., Chun, Y. S., and Park, J. W. (2006). A domain responsible for HIF-1alpha degradation by YC-1, a novel anticancer agent. Int. J. Oncol. 29, 255-260.
47. Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., et al. (2010). Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622. doi: 10.1200/JCO.2010.28.1386
48. Koch, C. J., and Evans, S. M. (2015). Optimizing hypoxia detection and treatment strategies. Semin. Nucl. Med. 45, 163-176. doi: 10.1053/j.semnuclmed.2014.10.004
49. Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., et al. (2008). Molecular mechanisms for the activity of PX-478, an antitumor inhibtor of the hypoxia-inducible factor-1alpha. Mol. Cancer Ther. 7, 90-100. doi: 10.1158/1535-7163.MCT-07-0463
50. Liang, W., Wu, X., Hong, S., Zhang, Y., Kang, S., and Fang, W. (2014). Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. PLoS ONE 9:e109757. doi: 10.1371/journal.pone.0109757
51. Lo Dico, A., Martelli, C., Valtorta, S., Raccagni, I., Diceglie, C., and Belloli, S. (2015). Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model. Eur. J. Nucl. Med. Mol. Imaging 42, 1093-1105. doi: 10.1007/s00259-015-3040-7
52. Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., et al. (2012). VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22, 21-35. doi: 10.1016/j.ccr.2012.05.037
53. Lupo, G., Motta, C., Salmeri, M., Spina-Purrello, V., Alberghina, M., and Anfuso, C. D. (2014). An in vitro retinoblastoma human triple culture model of angiogenesis: a modulatory effect of TGF-β. Cancer Lett. 354, 181-188. doi: 10.1016/j.canlet.2014.08.004
54. Maes, H., Olmeda, D., Soengas, M. S., and Agostinis, P. (2016). Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies. FEBS J. 283, 25-38. doi: 10.1111/febs.13545
55. Matsuda, K., Ohga, N., Hida, Y., Muraki, C., Tsuchiya, K., Kurosu, T., et al. (2010). Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem. Biophys. Res. Commun. 394, 947-954. doi: 10.1016/j.bbrc.2010.03.089
56. McIntyre, A., Patiar, S., Wigfield, S., Li, J., Ledaki, I., Turley, H., et al. (2012). Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapy. Clin. Cancer Res. 18, 3100-3111. doi: 10.1158/1078-0432.CCR-11-1877
57. McMillin, D. W., Negri, J. M., and Mitsiades, C. S. (2013). The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat. Rev. Drug Discov. 12, 217-228. doi: 10.1038/nrd3870
58. Meijer, T. W., Kaanders, J. H., Span, P. N., and Bussink, J. (2012). Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin. Cancer Res. 18, 5585-5594. doi: 10.1158/1078-0432.CCR-12-0858
59. Michaelson, M. D., Oudard, S., Ou, Y. C., Sengeløv, L., Saad, F., Houede, N., et al. (2014). Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J. Clin. Oncol. 32, 76-82. doi: 10.1200/JCO.2012.48.5268
60. Miller, K. D., Sweeney, C. J., and Sledge, G. W. Jr. (2005). Can tumor angiogenesis be inhibited without resistance? EXS 94, 95-112. doi: 10.1007/3-7643-7311-3_7
61. Moeller, B. J., and Dewhirst, M. W. (2006). HIF-1 and tumour radiosensitivity. Br. J. Cancer 95, 1-5. doi: 10.1038/sj.bjc.6603201
62. Nagy, J. A., and Dvorak, H. F. (2012). Heterogeneity of the tumor vasculature: the need for new tumour blood vessel type-specific targets. Clin. Exp. Metastasis 29, 657-662. doi: 10.1007/s10585-012-9500-6
63. Nanda, A., and Croix, B. S. (2004). Tumor endothelial markers: new targets for cancer therapy. Curr. Opin. Oncol. 16, 44-49. doi: 10.1097/00001622-200401000-00009
64. Nico, B., Crivellato, E., Guidolin, D., Annese, T., Longo, V., Finato, N., et al. (2010). Intussusceptive microvascular growth in human glioma. Clin. Exp. Med. 10, 93-98. doi: 10.1007/s10238-009-0076-7
65. Ohga, N., Ishikawa, S., Maishi, N., Akiyama, K., Hida, Y., Kawamoto, T., et al. (2012). Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from high-and low-metastatic tumors. Am. J. Pathol. 180, 1294-1307. doi: 10.1016/j.ajpath.2011.11.035
66. Paulsson, J., Sjöblom, T., Micke, P., Pontén, F., Landberg, G., Heldin, C. H., et al. (2009). Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. Am. J. Pathol. 175, 334-341. doi: 10.2353/ajpath.2009.081030
67. Powles, T., Kayani, I., Sharpe, K., Lim, L., Peters, J., Stewart, G. D., et al. (2013). A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer. Ann. Oncol. 24, 2098-2103. doi: 10.1093/annonc/mdt130
68. Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., et al. (2014). Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302-1308. doi: 10.1200/JCO.2013.51.4489
69. Rak, J., Yu, J. L., Kerbel, R. S., and Coomber, B. L. (2002). What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? Cancer Res. 62, 1931-1934.
70. Rini, B. I., Bellmunt, J., Clancy, J., Wang, K., Niethammer, A. G., Hariharan, S., et al. (2014). Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32, 752-759. doi: 10.1200/JCO.2013.50.5305
71. Russell, J. S., and Brown, J. M. (2013). The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery. Front. Physiol. 17:157. doi: 10.3389/fphys.2013.00157
72. Salmeri, M., Motta, C., Anfuso, C. D., Amodeo, A., Scalia, M., Toscano, M. A., et al. (2013). VEGF receptor-1 involvement in the pericyte loss induced by E. coli in an in vitro model of blood brain barrier. Cell. Microbiol. 8, 1367-1384. doi: 10.1111/cmi.12121
73. Saltz, L. B., Lenz, H.-J., Kindler, H. L., Hochster, H. S., Wadler, S., Hoff, P. M., et al. (2007). Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol. 25, 4557-4561. doi: 10.1200/JCO.2007.12.0949
74. Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 14, 2542-2550. doi: 10.1056/NEJMoa061884
75. Sattler, U. G., Meyer, S. S., Quennet, V., Hoerner, C., Knoerzer, H., Fabian, C., et al. (2010). Glycolytic metabolism and tumour response to fractionated irradiation. Radiother. Oncol. 94, 102-109. doi: 10.1016/j.radonc.2009.11.007
76. Schmidinger, M., and Bellmunt, J. (2010). Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat. Rev. 36, 416-424. doi: 10.1016/j.ctrv.2010.01.003
77. Seaman, S., Stevens, J., Yang, M. Y., Logsdon, D., Graff-Cherry, C., and St Croix, B. (2007). Genes that distinguish physiological and pathological angiogenesis. Cancer Cell 11, 539-554. doi: 10.1016/j.ccr.2007.04.017
78. Semenza, G. L. (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634. doi: 10.1038/onc.2009.441
79. Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A. M., et al. (2006). Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 22, 1785-1787. doi: 10.1126/science.1127592
80. Sharpe, K., Stewart, G. D., Mackay, A., Van Neste, C., Rofe, C., Berney, D., et al. (2013). The effect of VEGF targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. Clin. Cancer Res. 19, 6924-6934. doi: 10.1158/1078-0432.CCR-13-1631
81. Sherrill, K. W., Byrd, M. P., Van Eden, M. E., and Lloyd, R. E. (2004). BCL-2 translation is mediated via internal ribosome entry during cell stress. J. Biol. Chem. 279, 29066-29074. doi: 10.1074/jbc.M402727200
82. Shojaei, F., Wu, X., Zhong, C., Yu, L., Liang, X. H., Blanchard, D., et al. (2007). Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831. doi: 10.1038/nature06348
83. Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, A. M., et al. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J. Clin. Oncol. 33, 13-21. doi: 10.1200/JCO.2014.57.0572
84. Simpkins, F., Belinson, J. L., and Rose, P. G. (2007). Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening. Gynecol. Oncol. 107, 118-123. doi: 10.1016/j.ygyno.2007.06.004
85. Sitohy, B., Nagy, J. A., and Dvorak, H. F. (2012). Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 72, 1909-1914. doi: 10.1158/0008-5472.CAN-11-3406
86. Somers, J., Wilson, L. A., Kilday, J. P., Horvilleur, E., Cannell, I. G., Pöyry, T. A., et al. (2015). A common polymorphism in the 5' UTR of ERCC5 creates an upstream ORF that confers resistance to platinum-based chemotherapy. Genes Dev. 29, 1891-1896. doi: 10.1101/gad.261867.115
87. Straume, O., Chappuis, P. O., Salvesen, H. B., Halvorsen, O. J., Haukaas, S. A., Goffin, J., et al. (2002). Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers. Cancer Res. 62, 6808-6811.
88. Sun, M., Larcher, A., and Karakiewicz, P. I. (2014). Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. Int. J. Nephrol. Renovasc. Dis. 7, 401-407. doi: 10.2147/IJNRD.S48496
89. Takata, S., Masuda, T., Nakamura, S., Kuchimaru, T., Tsuruma, K., Shimazawa, M., et al. (2015). The effect of triamcinolone acetonide on laser-induced choroidal neovascularization in mice using a hypoxia visualization bio-imaging probe. Sci. Rep. 30:9898. doi: 10.1038/srep09898
90. Taylor, S. M., Nevis, K. R., Park, H. L., Rogers, G. C., Rogers, S. L., Cook, J. G., et al. (2010). Angiogenic factor signaling regulates centrosome duplication in endothelial cells of developing blood vessels. Blood 116, 3108-3117. doi: 10.1182/blood-2010-01-266197
91. Teng, L. S., Jin, K. T., He, K. F., Wang, H. H., Cao, J., and Yu, D. C. (2010). Advances in combination of antiangiogenic agents targeting VEGF-binding and conventional chemotherapy and radiation for cancer treatment. J. Chin. Med. Assoc. 73, 281-288. doi: 10.1016/S1726-4901(10)70062-9
92. Tewari, K. S., Sill, M. W., Long, H. J. III, Penson, R. T., Huang, H., Ramondetta, L. M., et al. (2014). Improved survival with bevacizumab in advanced cervical cancer. N. Engl. J. Med. 370, 734-743. doi: 10.1056/NEJMoa1309748
93. Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., et al. (2015). Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc. Natl. Acad. Sci. U.S.A. 112, 14325-14330. doi: 10.1073/pnas
94. Tsao, A. S., Liu, S., Fujimoto, J., Wistuba, I. I., Lee, J. J., Marom, E. M., et al. (2011). Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J. Thorac. Oncol. 6, 2104-2111. doi: 10.1097/JTO.0b013e31822e7256
95. Uniacke, J., Holterman, C. E., Lachance, G., Franovic, A., Jacob, M. D., Fabian, M. R., et al. (2012). An oxygen-regulated switch in the protein synthesis machinery. Nature 486, 126-129. doi: 10.1038/nature11055
96. Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., et al. (2010). Glioblastoma stem-like cells give rise to tumor endothelium. Nature 468, 829-833. doi: 10.1038/nature09624
97. Wilke, H., Muro, K., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., et al. (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224-1235. doi: 10.1016/S1470-2045(14)70420-6
98. Winkler, F., Kozin, S. V., Tong, R. T., Chae, S. S., Booth, M. F., Garkavtsev, I., et al. (2004). Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6, 553-563. doi: 10.1016/j.ccr.2004.10.011
99. Xian, X., Håkansson, J., Ståhlberg, A., Lindblom, P., Betsholtz, C., Gerhardt, H., et al. (2006). Pericytes limit tumor cell metastasis. J. Clin. Invest. 116, 642-651. doi: 10.1172/JCI25705
100. Xu, J., Wang, J., Xu, B., Ge, H., Zhou, X., and Fang, J. Y. (2013). Colorectal cancer cells refractory to anti-VEGF treatment are vulnerable to glycolytic blockade due to persistent impairment of mitochondria. Mol. Cancer Ther. 12, 717-724. doi: 10.1158/1535-7163.MCT-12-1016-T
101. Yonenaga, Y., Mori, A., Onodera, H., Yasuda, S., Oe, H., Fujimoto, A., et al. (2005). Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 69, 159-166. doi: 10.1159/000087840
102. Yu, J. L., Rak, J. W., Coomber, B. L., Hicklin, D. J., and Kerbel, R. S. (2002). Effect of p53 status on tumor response to antiangiogenic therapy. Science 22, 1526-1528. doi: 10.1126/science.1068327